

1 **WO**

2

3

4

5

6

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF ARIZONA**

7

8

9

Clerisy Corporation, et al.,) CV 12-2110-PHX-PGR

10

Plaintiffs,)

11

v.) **ORDER**

12

Airware Holdings, Inc., et al.,)

13

Defendants.)

14

Before the Court is Plaintiffs’ motion to dismiss all claims and counterclaims without prejudice. (Doc. 109.) Defendants have filed a cross-motion for attorneys’ fees and costs. (Doc. 110.) For the reasons set forth herein, the Court will grant Plaintiffs’ motion to dismiss and deny Defendants’ cross-motion.

15

16

17

18

19

BACKGROUND

20

Plaintiff Reed Transition Technologies, LLC, owns a patent for an “Apparatus for and Methods of Administering Volatile Substances into an Inhalation Flow Path.” Plaintiff Clerisy Corp. manufactures, markets, and distributes Aromahaler® Nasal SoftStrips™ using the patented apparatus. Defendants market, sell, and distribute “AIR” branded nasal products, which, like the Nasal SoftStrips, are infused with essential oils.

21

22

23

24

25

Plaintiffs filed a complaint in the Western District of New York alleging that Defendants are infringing the Patent. The case was transferred to the District of Arizona on Defendant’s motion. Plaintiffs filed an amended complaint, and Defendants filed an answer and counterclaims.

26

27

28

1 **1. Rule 41(a)(2)**

2 Rule 41(a)(2) provides that unless a plaintiff files a notice of dismissal before the
3 opposing party serves either an answer or a motion for summary judgment, or the parties
4 stipulate to the dismissal of the action, “[a]n action may be dismissed at the plaintiff’s request
5 only by court order, on terms that the court considers proper.” Fed. R. Civ. P. 41(a)(2). A
6 motion for voluntary dismissal pursuant to Rule 41(a)(2) should be granted unless a
7 defendant can show that it will suffer some plain legal prejudice as a result of the dismissal.
8 *Smith v. Lenches*, 263 F.3d 972, 975 (9th Cir. 2001). As noted, Defendants do not make such
9 a showing.

10 A court has the discretion to condition a dismissal without prejudice upon the payment
11 of “appropriate costs and attorney fees.” *Westlands Water Dist. v. United States*, 100 F.3d
12 94, 96 (9th Cir. 1996). The payment of fees is not, however, a prerequisite to a Rule 41(a)
13 dismissal. *Stevedoring Servs. of Am. v. Armilla Intern. B. V.*, 889 F.2d 919, 921 (9th Cir.
14 1989) (explaining that “no circuit court has held that payment of the defendant’s costs and
15 attorney fees is a prerequisite to an order granting voluntary dismissal”); *see Westlands*, 100
16 F.3d at 97 (“Imposition of costs and fees as a condition for dismissing without prejudice is
17 not mandatory.”).

18 In arguing for an award of fees under Rule 41(a)(2), Defendants assert that “in cases
19 where the litigation has proceeded to the point that the defendant has incurred significant fees
20 and costs, the courts ordinarily condition a dismissal without prejudice on the plaintiff’s
21 reimbursement of the defendant’s fees and costs incurred during the litigation.” (Doc. 110
22 at 8.) In support of this position Defendants rely on *McCants v. Ford Motor Co.*, 781 F.2d
23 855 (11th Cir. 1986). There, the Eleventh Circuit stated that “[a] plaintiff ordinarily will not
24 be permitted to dismiss an action without prejudice under Rule 41(a)(2) after the defendant
25 has been put to considerable expense in preparing for trial, except on condition that the
26 plaintiff reimburse the defendant for at least a portion of his expenses of litigation.”
27 *McCants*, 781 F.2d at 860.
28

1 Defendants' argument is not persuasive in the light of Ninth Circuit law. In
2 *Heckethorn v. Sunan Corp.*, 992 F.2d 240, 242 (9th Cir. 1993), the court held that
3 "Fed.R.Civ.P. 41(a)(2) in itself is not 'specific statutory authority' for the imposition of
4 sanctions against an attorney." Thus, this Court must have an "independent basis" to impose
5 fees and costs as a condition of voluntary dismissal. *Chavez v. Northland Group*, No. CV-09-
6 2521-PHX-LOA, 2011 WL 317482, at *3 (D.Ariz. February 1, 2011) (citing *Heckethorn*,
7 992 F.2d at 242); see *Chang v. Pomeroy*, No. CIV-S-08-657-FCDS-DAD-PS, 2011 WL
8 618192, at *1 (E.D.Cal. Feb. 10, 2011) (explaining that "a court cannot impose fees and costs
9 as a condition of voluntary dismissal absent some basis other than the mere fact of the
10 plaintiff's request for Rule 41(a)(2).").

11 While the Court agrees with Defendants that it retains the discretion to condition
12 dismissal on an award of attorneys' fees, it finds no basis to do so here. A fee award is
13 particularly inappropriate in this case, given that Plaintiffs' have executed a covenant not to
14 sue. Defendants face no threat of future, duplicative litigation. "The covenant not to sue
15 precludes the possibility of relitigation of this matter, and therefore an award of fees and
16 costs, which is designed to protect defendants from the expense of defending an action again,
17 is not required." *Furminator, Inc. v. Ontel Products Corp.*, 246 F.R.D. 579, 596 (E.D.Mo.
18 2007); see *Gap, Inc. v. Stone Intern. Trading, Inc.*, 169 F.R.D. 584, 589 (S.D.N.Y. 1997)
19 ("The Gap's offer of a covenant not to sue obviates the need to reimburse the defendants on
20 this ground, however, since there is no possibility of relitigation."); see also *Colombrito v.*
21 *Kelly*, 764 F.2d 122, 134 (2d Cir. 1985) ("The purpose of such awards is generally to
22 reimburse the defendant for the litigation costs incurred, in view of the risk (often the
23 certainty) faced by the defendant that the same suit will be refiled and will impose
24 duplicative expenses upon him.").

25 The Court will next consider the argument that 28 U.S.C. § 1927 provides a basis for
26 the recovery of Defendants' attorneys' fees.
27
28

1 **2. 28 U.S.C. § 1927**

2 A court may impose sanctions against an attorney under 28 U.S.C. § 1927, which
3 provides that, “Any attorney or other person admitted to conduct cases in any court of the
4 United States or any Territory thereof who so multiplies the proceedings in any case
5 unreasonably and vexatiously may be required by the court to satisfy personally the excess
6 costs, expenses, and attorneys’ fees reasonably incurred because of such conduct.”

7 Sanctions may be imposed under § 1927 where there is a finding of bad faith or
8 recklessness. *See Lahiri v. Universal Music & Video Distribution Corp.*, 606 F.3d 1216,
9 1219 (9th Cir. 2010); *Pacific Harbor Capital, Inc. v. Carnival Air Lines, Inc.*, 210 F.3d 1112,
10 1118 (9th Cir. 2000). Bad faith is assessed “under a subjective standard. Knowing or reckless
11 conduct meets this standard.” *MGIC Indem. Corp. v. Moore*, 952 F.2d 1120, 1121–22 (9th
12 Cir. 1991). “[T]he term ‘vexatious’ has been defined as ‘lacking justification and intended
13 to harass.’” *Terrebonne, Ltd. of California v. Murray*, 1 F.Supp.2d 1050, 1055
14 (E.D.Cal.,1998) (quoting *Overnite Transp. Co. v. Chicago Ind. Tire Co.*, 697 F.2d 789, 795
15 (7th Cir.1983)). Courts have characterized § 1927 as imposing an “extreme standard, *White*
16 *v. American Airlines, Inc.*, 915 F.2d 1414, 1427 (10th Cir. 1990), which should be “sparingly
17 applied,” *F.D.I.C. v. Calhoun*, 34 F.3d 1291, 1297 (5th Cir. 1994).

18 Defendants asserts that Plaintiffs’ pursuit of their patent infringement claims was
19 vexatious and unreasonable because “[t]he evidence has established at every stage of this
20 case that AirWare’s accused products do not incorporate any ‘barrier’ that prevents the
21 essential oil molecules on the device from coming into contact with the user’s skin.”¹ (Doc.
22 110 at 9.) According to Defendants, therefore, Plaintiffs pursued the claims despite knowing
23 that Defendants’ product did not infringe the patent. Defendants recount the following events
24

25 ¹ The patent claimed both a “carrier,” defined as “[t]he portion of the vehicle or device
26 that carries or provides at least one volatile substance,” and a “barrier,” “[t]he portion of the
27 vehicle or device that prevents contact between the skin and the volatile substance.” (*See*
28 Doc. 102 at 5.)

1 in support of their argument that Plaintiffs were aware that Defendants' products did not
2 contain a barrier.

3 – Before filing suit, Plaintiffs and their attorneys obtained samples of Defendant
4 AirWare's products "and should have known then that the products did not have a barrier."
5 (Doc. 110 at 5.)

6 – On August 10, 2012, two weeks after Plaintiffs filed their complaint, and again on
7 August 24, AirWare's counsel sent Rule 11 notice letters to Plaintiffs' counsel stating that
8 the accused products "do not include a barrier as required in the '982 patent" and demanded
9 that Plaintiffs dismiss the suit. (Doc. 111, Ex's G, H.)

10 – On July 25, 2013, AirWare's founder, David Dolezal, testified at his deposition
11 that there is no "structure or part of the accused products that prevent the molecules of the
12 essential oils from coming into contact with the inside of the nose" and that molecules of the
13 essential oils do in fact come into contact with the skin. (*Id.*, Ex. B at 71.)

14 – On August 16, 2013, Michael Doll, AirWare's Rule 30(b)(6) witness, testified that
15 nothing in the accused products prevents the oil molecules from contacting the skin of the
16 user. (*Id.*, Ex. I.)

17 Plaintiffs counter that they have acted reasonably and in good faith because the
18 infringement of their patent by Defendants' products was genuinely in dispute. Plaintiffs
19 contest Defendants' argument that the absence of a barrier in their products was an
20 "unequivocal" fact and known to Plaintiffs from the outset of the case. Plaintiffs assert that
21 the following facts support their position.

22 – Before the lawsuit was filed, AirWare's CEO, Jeffrey Rassás, represented to
23 Plaintiff Clerisy's CEO and President, Dr. Mary Maida, that the Accused Products were
24 designed and manufactured so that the essential oils on the Accused Products did not touch
25 the skin or inside lining of the nose. (*See* Doc. 114.)

26 – In the parties' Joint Case Management Report, filed on January 14, 2013,
27 Defendants represented that "whether Defendants are directly and/or inducing and/or
28

1 contributing to the infringement of at least one valid claim of the '982 Patent" was
2 "genuinely in dispute." (Doc. 71 at 11.) In the report Plaintiffs set forth their position with
3 respect to the presence of a barrier in Defendants' products, recounting the information
4 received from Mr. Rasás:

5 Airware's CEO, Jeffrey Rassás, confirmed to Clerisy's President and CEO, Dr.
6 Mary Maida, before this lawsuit was filed that AirWare's products were
7 specifically designed and manufactured so that essential oils do not touch the
8 skin or the inside lining of the nose. Mr. Rassás acknowledged that when
9 AirWare was designing its infused products, there was a concern about the
10 essential oils touching the inside of the nose, due to irritation of the skin.
Because of this concern, Mr. Rassás stated that AirWare's products were
designed and manufactured so that there are no essential oils on the ring that
touches the inside of the nose, and that the essential oils in the products do not
touch the skin in any way.

11 (*Id.* at 5.) Defendants generally denied infringement but did not respond to this allegation
12 specifically. (*Id.* at 8.)

13 – The Court's claims construction order rejected Defendants' narrow construction
14 of the term barrier, concluding that the patent did not require the presence of "distinct"
15 barrier and carrier layers. (Doc. 102 at 7–9.)

16 – It was only after the order was issued that Defendants offered their argument that
17 molecules of the essential oils come into contact with the skin.

18 – Defendants have offered no technical documents in support of the argument that
19 their products do not include a barrier.

20 – Although they now assert that it was unequivocal that their products did not
21 include a barrier, Defendants never filed a motion for summary judgment of non-
22 infringement.

23 – In September 2013, when the parties discussed a mutual dismissal of all claims and
24 counterclaims, Defendants refused to execute an affidavit stating: "When Airware's infused
25 products . . . are placed in a user's nasal passage, the essential oils contained on such infused
26 products come into direct contact with the inside lining of the user's nasal passage." (Doc.
27 114, ¶¶18–20; Ex. B.)

28


1 IT IS FURTHER ORDERED DENYING Defendants' cross-motion for attorneys'
2 fees (Doc. 110).

3 IT IS FURTHER ORDERED DENYING as moot Defendants' motion to compel
4 responses (Doc. 95), Plaintiffs' motion to compel (Doc. 97), Plaintiff's motion for a
5 protective order (Doc. 107), and Plaintiffs' motion to file a surreply (Doc. 117).

6 IT IS FURTHER ORDERED that the Clerk of Court shall enter judgment
7 accordingly.

8 DATED this 3rd day of December, 2013.

9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28



Paul G. Rosenblatt
United States District Judge